Prostate cancer patient selection. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Anatomy9

Prostate Cell Line, Tumor Tumor Cells, Cultured Epithelial Cells Neoplastic Stem Cells Chromosomes, Human, Pair 8 Seminal Vesicles Rectum Stromal Cells

Organisms4

Mice, Nude Mice, SCID Mice, Transgenic Mice, Inbred BALB C

Diseases34

Prostatic Neoplasms Prostatic Hyperplasia Neoplasms, Hormone-Dependent Adenocarcinoma Neoplasm Metastasis Disease Progression Prostatic Intraepithelial Neoplasia Bone Neoplasms Neoplasm Invasiveness Neoplasms Neoplasm Recurrence, Local Breast Neoplasms Genetic Predisposition to Disease Lung Neoplasms Carcinoma Ovarian Neoplasms Prostatic Neoplasms, Castration-Resistant Postoperative Complications Colonic Neoplasms Pancreatic Neoplasms Colorectal Neoplasms Stomach Neoplasms Cell Transformation, Neoplastic Prostatic Diseases Liver Neoplasms Carcinoma, Non-Small-Cell Lung Prostatitis Rectal Neoplasms Urinary Bladder Neoplasms Neovascularization, Pathologic Carcinoma, Squamous Cell Recurrence Disease Models, Animal Uterine Cervical Neoplasms

Chemicals and Drugs60

Prostate-Specific Antigen Receptors, Androgen Androgens Androgen Antagonists Tumor Markers, Biological Antineoplastic Agents Tosyl Compounds Antineoplastic Agents, Hormonal Neoplasm Proteins Androgen Receptor Antagonists RNA, Messenger Anilides Dihydrotestosterone Finasteride Metribolone RNA, Small Interfering Flutamide Anticarcinogenic Agents Cancer Vaccines Taxoids Glutamate Carboxypeptidase II 5-alpha Reductase Inhibitors DNA, Neoplasm PTEN Phosphohydrolase Testosterone Congeners Antigens, Neoplasm Antibodies, Monoclonal Antineoplastic Agents, Phytogenic Testosterone Androstenols Receptor, erbB-2 3-Oxo-5-alpha-Steroid 4-Dehydrogenase Nitriles Azasteroids Phenylthiohydantoin Proto-Oncogene Proteins c-akt Transcription Factors Receptor, Epidermal Growth Factor Tumor Suppressor Protein p53 RNA, Neoplasm Racemases and Epimerases MicroRNAs Protein Kinase Inhibitors Cholestenone 5 alpha-Reductase Tumor Suppressor Proteins DNA-Binding Proteins Estramustine Leuprolide DNA Primers Goserelin Genetic Markers Glutathione S-Transferase pi Receptors, Estrogen Antibodies, Monoclonal, Humanized Proto-Oncogene Proteins Radiopharmaceuticals Enzyme Inhibitors Proto-Oncogene Proteins c-bcl-2 Prostatic Secretory Proteins Androgen-Binding Protein

Analytical, Diagnostic and Therapeutic Techniques and Equipment90

Patient Selection Prostatectomy Treatment Outcome Orchiectomy Early Detection of Cancer Prognosis Retrospective Studies Neoplasm Staging Risk Factors Follow-Up Studies Risk Assessment Prospective Studies Survival Rate Neoplasm Grading Survival Analysis Clinical Trials as Topic Reverse Transcriptase Polymerase Chain Reaction Gene Expression Profiling Predictive Value of Tests Xenograft Model Antitumor Assays Sensitivity and Specificity Digital Rectal Examination Combined Modality Therapy Neoplasm Transplantation Risk Transplantation, Heterologous Cohort Studies Biopsy Immunohistochemistry Brachytherapy Multivariate Analysis Disease-Free Survival Case-Control Studies Blotting, Western Reproducibility of Results Transurethral Resection of Prostate Registries Odds Ratio Kaplan-Meier Estimate Antineoplastic Combined Chemotherapy Protocols Molecular Targeted Therapy Incidence Logistic Models Oligonucleotide Array Sequence Analysis Biopsy, Needle Transfection Radiotherapy Dosage Tomography, X-Ray Computed Tumor Burden Polymerase Chain Reaction Questionnaires Tissue Array Analysis Models, Biological Models, Genetic Castration SEER Program Chemotherapy, Adjuvant Radiotherapy Proportional Hazards Models Randomized Controlled Trials as Topic Nomograms Drug Screening Assays, Antitumor ROC Curve Feasibility Studies Radiotherapy, Conformal Treatment Failure Flow Cytometry Magnetic Resonance Imaging Immunotherapy Preoperative Care Research Design Mass Screening Positron-Emission Tomography Confidence Intervals Gene Knockdown Techniques Fetal Therapies Clinical Trials, Phase I as Topic Clinical Trials, Phase III as Topic Disease Models, Animal Regression Analysis Diagnostic Imaging Immunoenzyme Techniques Chi-Square Distribution Radiotherapy, Adjuvant Salvage Therapy Cryosurgery In Situ Hybridization, Fluorescence Reoperation Drug Delivery Systems Radiotherapy, Intensity-Modulated

Psychiatry and Psychology1

Decision Making

Phenomena and Processes48

Selection, Genetic Gene Expression Regulation, Neoplastic Cell Proliferation Time Factors Apoptosis Genetic Predisposition to Disease Sensitivity and Specificity Drug Resistance, Neoplasm Risk Mutation Signal Transduction Genotype Odds Ratio Cell Growth Processes Down-Regulation Cell Division Polymorphism, Genetic Cell Survival Base Sequence Transfection Cell Movement Genetic Variation Promoter Regions, Genetic DNA Methylation Alleles Up-Regulation Cell Cycle Phenotype Dose-Response Relationship, Drug Polymorphism, Single Nucleotide Algorithms Gene Silencing Gene Fusion Nomograms Gene Expression RNA Interference Genes, Tumor Suppressor Chromosomes, Human, Pair 8 Transcription, Genetic Phosphorylation Diet Genetic Markers Chi-Square Distribution Amino Acid Sequence Evolution, Molecular Genes, Neoplasm Gene Frequency Germ-Line Mutation

Disciplines and Occupations3

Immunohistochemistry Medical Oncology Research Design

Anthropology, Education, Sociology and Social Phenomena4

Teaching Rounds Quality of Life National Cancer Institute (U.S.)Forecasting

Humanities1

Quality of Life

Information Science11

Survival Rate Registries Incidence Molecular Sequence Data Base Sequence Questionnaires SEER Program Algorithms Radiotherapy, Conformal Amino Acid Sequence Radiotherapy, Intensity-Modulated

Named Groups3

European Continental Ancestry Group African Americans Survivors

Health Care42

Patient Selection Treatment Outcome Retrospective Studies Risk Factors Follow-Up Studies Risk Assessment Prospective Studies Survival Rate Survival Analysis Clinical Trials as Topic Predictive Value of Tests Sensitivity and Specificity Watchful Waiting Risk Cohort Studies Multivariate Analysis Disease-Free Survival Age Factors Case-Control Studies Reproducibility of Results Registries Odds Ratio Kaplan-Meier Estimate Incidence Logistic Models Questionnaires SEER Program National Cancer Institute (U.S.)Proportional Hazards Models Randomized Controlled Trials as Topic Nomograms ROC Curve Feasibility Studies Treatment Failure Preoperative Care Mass Screening Confidence Intervals Clinical Trials, Phase I as Topic Clinical Trials, Phase III as Topic Regression Analysis Chi-Square Distribution Selection Bias

Geographicals3

United States Europe Sweden

Anatomy Organisms Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Phenomena and Processes Disciplines and Occupations Anthropology, Education, Sociology and Social Phenomena Humanities Information Science Named Groups Health Care Geographicals

Prostate Patient Selection Prostatic Neoplasms Prostate-Specific Antigen Selection, Genetic Receptors, Androgen Androgens Cell Line, Tumor Prostatectomy Androgen Antagonists Treatment Outcome Prostatic Hyperplasia Gene Expression Regulation, Neoplastic Orchiectomy Neoplasms, Hormone-Dependent Tumor Markers, Biological Adenocarcinoma Neoplasm Metastasis Disease Progression Early Detection of Cancer Prognosis Retrospective Studies Antineoplastic Agents Mice, Nude Neoplasm Staging Risk Factors Prostatic Intraepithelial Neoplasia Follow-Up Studies Tosyl Compounds Risk Assessment Prospective Studies Bone Neoplasms Neoplasm Invasiveness Survival Rate Neoplasm Grading Neoplasms Cell Proliferation Time Factors Survival Analysis Neoplasm Recurrence, Local Tumor Cells, Cultured Breast Neoplasms Apoptosis Genetic Predisposition to Disease Clinical Trials as Topic Antineoplastic Agents, Hormonal Reverse Transcriptase Polymerase Chain Reaction Neoplasm Proteins Androgen Receptor Antagonists Lung Neoplasms Gene Expression Profiling Predictive Value of Tests Xenograft Model Antitumor Assays RNA, Messenger Sensitivity and Specificity Digital Rectal Examination Drug Resistance, Neoplasm United States Anilides Combined Modality Therapy Watchful Waiting Neoplasm Transplantation Risk Carcinoma Dihydrotestosterone Mutation Signal Transduction Transplantation, Heterologous Finasteride Cohort Studies Biopsy Genotype Immunohistochemistry Brachytherapy Multivariate Analysis Disease-Free Survival Age Factors Case-Control Studies Blotting, Western Teaching Rounds Reproducibility of Results Metribolone Transurethral Resection of Prostate Registries Odds Ratio Kaplan-Meier Estimate Cell Growth Processes Antineoplastic Combined Chemotherapy Protocols Molecular Targeted Therapy RNA, Small Interfering Incidence Ovarian Neoplasms Prostatic Neoplasms, Castration-Resistant Flutamide Logistic Models Down-Regulation Molecular Sequence Data Postoperative Complications Cell Division Anticarcinogenic Agents

No FAQ available that match "prostate cancer patient selection"